Clinical trial
A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in…
NCT00484939 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00484939 |
|---|---|
| Title | A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer |
| Official title | A Randomised, Open-label Phase III Study to Assess Efficacy and Safety of Bevacizumab in Combination With Capecitabine as First-line Treatment for Elderly Patients With Metastatic Colorectal Cancer |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Capecitabine |
| Enrollment | 280 |
| Start date | Jul 1, 2007 |
| Primary completion | Mar 1, 2013 |
| Completion | Mar 1, 2013 |
| First posted | Jun 12, 2007 |
| Last update posted | Jan 8, 2015 |
| Countries | Austria, Canada, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Slovenia, South Korea, Spain, United Kingdom |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: